Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK™ (tisotumab vedotin-tftv) Approval

Rhea-AI Summary

Seagen Inc. (NASDAQ: SGEN) will hold a conference call on September 21, 2021, at 6:00 a.m. PT to discuss the FDA approval of TIVDAK™ (tisotumab vedotin-tftv). Investors can access the call via telephone at 844-763-8274 in the U.S. or +1 412-717-9224 internationally, using conference ID 10160278. A webcast will also be available on the Seagen website, featuring slides and a replay. Seagen, based in Seattle, Washington, focuses on developing transformative cancer therapies.

BOTHELL, Wash.--(BUSINESS WIRE)-- Seagen Inc. (Nasdaq: SGEN) will host a conference call and webcast on Tuesday, September 21, 2021 to discuss the U.S. Food and Drug Administration approval of TIVDAK™ (tisotumab vedotin-tftv). Access to the event can be obtained as follows:

September 21, 2021

6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time

• Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international); conference ID 10160278
• Webcast with slides will be available at www.seagen.com in the Investors section. A webcast replay will be archived on the Company’s website.

About Seagen

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210920005929/en/

For Investors

Peggy Pinkston

Senior Vice President, Investor Relations

(425) 527-4160

ppinkston@seagen.com

For Media

David Caouette

Vice President, Corporate Communications

(310) 430-3476

dcaouette@seagen.com

Source: Seagen Inc.

FAQ

When is Seagen's conference call to discuss TIVDAK approval?

Seagen's conference call is scheduled for September 21, 2021, at 6:00 a.m. Pacific Time.

How can I access Seagen's conference call on TIVDAK?

You can access the call by calling 844-763-8274 in the U.S. or +1 412-717-9224 internationally, using conference ID 10160278.

Where can I find the webcast for Seagen's conference call?

The webcast will be available on the Seagen website in the Investors section.

What is TIVDAK and why is it significant for Seagen?

TIVDAK (tisotumab vedotin-tftv) is a drug that received FDA approval, marking an important milestone for Seagen in cancer treatment.

What does Seagen focus on in the biotechnology sector?

Seagen focuses on discovering, developing, and commercializing transformative cancer medicines.